GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Aclaris Therapeutics Inc (FRA:8AT) » Definitions » E10

Aclaris Therapeutics (FRA:8AT) E10 : €-2.18 (As of Sep. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Aclaris Therapeutics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Aclaris Therapeutics's adjusted earnings per share data for the three months ended in Sep. 2024 was €-0.099. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-2.18 for the trailing ten years ended in Sep. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2024-12-14), Aclaris Therapeutics's current stock price is €3.095. Aclaris Therapeutics's E10 for the quarter that ended in Sep. 2024 was €-2.18. Aclaris Therapeutics's Shiller PE Ratio of today is .


Aclaris Therapeutics E10 Historical Data

The historical data trend for Aclaris Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aclaris Therapeutics E10 Chart

Aclaris Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -2.22

Aclaris Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -2.22 -2.29 -2.33 -2.18

Competitive Comparison of Aclaris Therapeutics's E10

For the Diagnostics & Research subindustry, Aclaris Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aclaris Therapeutics's Shiller PE Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Aclaris Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Aclaris Therapeutics's Shiller PE Ratio falls into.



Aclaris Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Aclaris Therapeutics's adjusted earnings per share data for the three months ended in Sep. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-0.099/133.0289*133.0289
=-0.099

Current CPI (Sep. 2024) = 133.0289.

Aclaris Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201412 -0.248 99.070 -0.333
201503 -0.284 99.621 -0.379
201506 -0.150 100.684 -0.198
201509 -0.535 100.392 -0.709
201512 -0.257 99.792 -0.343
201603 -0.584 100.470 -0.773
201606 -0.552 101.688 -0.722
201609 -0.445 101.861 -0.581
201612 -0.465 101.863 -0.607
201703 -0.449 102.862 -0.581
201706 -0.498 103.349 -0.641
201709 -0.529 104.136 -0.676
201712 -0.625 104.011 -0.799
201803 -0.795 105.290 -1.004
201806 -0.865 106.317 -1.082
201809 -0.908 106.507 -1.134
201812 -0.870 105.998 -1.092
201903 -0.805 107.251 -0.998
201906 -1.071 108.070 -1.318
201909 -1.217 108.329 -1.494
201912 -0.405 108.420 -0.497
202003 -0.335 108.902 -0.409
202006 -0.249 108.767 -0.305
202009 -0.212 109.815 -0.257
202012 -0.247 109.897 -0.299
202103 -0.479 111.754 -0.570
202106 -0.282 114.631 -0.327
202109 -0.298 115.734 -0.343
202112 -0.327 117.630 -0.370
202203 -0.281 121.301 -0.308
202206 -0.293 125.017 -0.312
202209 -0.303 125.227 -0.322
202212 -0.387 125.222 -0.411
202303 -0.392 127.348 -0.409
202306 -0.388 128.729 -0.401
202309 -0.384 129.860 -0.393
202312 -0.018 129.419 -0.019
202403 -0.221 131.776 -0.223
202406 -0.139 132.554 -0.139
202409 -0.099 133.029 -0.099

Add all the adjusted EPS together and divide 10 will get our e10.


Aclaris Therapeutics  (FRA:8AT) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Aclaris Therapeutics E10 Related Terms

Thank you for viewing the detailed overview of Aclaris Therapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Aclaris Therapeutics Business Description

Traded in Other Exchanges
Address
701 Lee Road, Suite 103, Wayne, PA, USA, 19087
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.

Aclaris Therapeutics Headlines

No Headlines